Status Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis

Intra-arterial drug delivery circumvents the first-pass effect and is believed to increase both efficacy and tolerability of primary and metastatic brain tumor therapy. The aim of this update is to report on pertinent articles and clinical trials to better understand the research landscape to date a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Julian S. Rechberger, Frederic Thiele, David J. Daniels
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	brain tumor glioma drug delivery injection intra-arterial chemotherapy Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/4e4a8c5b19bf4841b7947a7a716eb304
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4e4a8c5b19bf4841b7947a7a716eb304
record_format	dspace
spelling	oai:doaj.org-article:4e4a8c5b19bf4841b7947a7a716eb3042021-11-25T18:41:27ZStatus Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis10.3390/pharmaceutics131118851999-4923https://doaj.org/article/4e4a8c5b19bf4841b7947a7a716eb3042021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1885https://doaj.org/toc/1999-4923Intra-arterial drug delivery circumvents the first-pass effect and is believed to increase both efficacy and tolerability of primary and metastatic brain tumor therapy. The aim of this update is to report on pertinent articles and clinical trials to better understand the research landscape to date and future directions. Elsevier’s Scopus and ClinicalTrials.gov databases were reviewed in August 2021 for all possible articles and clinical trials of intra-arterial drug injection as a treatment strategy for brain tumors. Entries were screened against predefined selection criteria and various parameters were summarized. Twenty clinical trials and 271 articles satisfied all inclusion criteria. In terms of articles, 201 (74%) were primarily clinical and 70 (26%) were basic science, published in a total of 120 different journals. Median values were: publication year, 1986 (range, 1962–2021); citation count, 15 (range, 0–607); number of authors, 5 (range, 1–18). Pertaining to clinical trials, 9 (45%) were phase 1 trials, with median expected start and completion years in 2011 (range, 1998–2019) and 2022 (range, 2008–2025), respectively. Only one (5%) trial has reported results to date. Glioma was the most common tumor indication reported in both articles (68%) and trials (75%). There were 215 (79%) articles investigating chemotherapy, while 13 (65%) trials evaluated targeted therapy. Transient blood–brain barrier disruption was the commonest strategy for articles (27%) and trials (60%) to optimize intra-arterial therapy. Articles and trials predominately originated in the United States (50% and 90%, respectively). In this bibliometric and clinical trials analysis, we discuss the current state and trends of intra-arterial therapy for brain tumors. Most articles were clinical, and traditional anti-cancer agents and drug delivery strategies were commonly studied. This was reflected in clinical trials, of which only a single study had reported outcomes. We anticipate future efforts to involve novel therapeutic and procedural strategies based on recent advances in the field.Julian S. RechbergerFrederic ThieleDavid J. DanielsMDPI AGarticlebrain tumorgliomadrug deliveryinjectionintra-arterialchemotherapyPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1885, p 1885 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	brain tumor glioma drug delivery injection intra-arterial chemotherapy Pharmacy and materia medica RS1-441
spellingShingle	brain tumor glioma drug delivery injection intra-arterial chemotherapy Pharmacy and materia medica RS1-441 Julian S. Rechberger Frederic Thiele David J. Daniels Status Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis
description	Intra-arterial drug delivery circumvents the first-pass effect and is believed to increase both efficacy and tolerability of primary and metastatic brain tumor therapy. The aim of this update is to report on pertinent articles and clinical trials to better understand the research landscape to date and future directions. Elsevier’s Scopus and ClinicalTrials.gov databases were reviewed in August 2021 for all possible articles and clinical trials of intra-arterial drug injection as a treatment strategy for brain tumors. Entries were screened against predefined selection criteria and various parameters were summarized. Twenty clinical trials and 271 articles satisfied all inclusion criteria. In terms of articles, 201 (74%) were primarily clinical and 70 (26%) were basic science, published in a total of 120 different journals. Median values were: publication year, 1986 (range, 1962–2021); citation count, 15 (range, 0–607); number of authors, 5 (range, 1–18). Pertaining to clinical trials, 9 (45%) were phase 1 trials, with median expected start and completion years in 2011 (range, 1998–2019) and 2022 (range, 2008–2025), respectively. Only one (5%) trial has reported results to date. Glioma was the most common tumor indication reported in both articles (68%) and trials (75%). There were 215 (79%) articles investigating chemotherapy, while 13 (65%) trials evaluated targeted therapy. Transient blood–brain barrier disruption was the commonest strategy for articles (27%) and trials (60%) to optimize intra-arterial therapy. Articles and trials predominately originated in the United States (50% and 90%, respectively). In this bibliometric and clinical trials analysis, we discuss the current state and trends of intra-arterial therapy for brain tumors. Most articles were clinical, and traditional anti-cancer agents and drug delivery strategies were commonly studied. This was reflected in clinical trials, of which only a single study had reported outcomes. We anticipate future efforts to involve novel therapeutic and procedural strategies based on recent advances in the field.
format	article
author	Julian S. Rechberger Frederic Thiele David J. Daniels
author_facet	Julian S. Rechberger Frederic Thiele David J. Daniels
author_sort	Julian S. Rechberger
title	Status Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis
title_short	Status Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis
title_full	Status Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis
title_fullStr	Status Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis
title_full_unstemmed	Status Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis
title_sort	status quo and trends of intra-arterial therapy for brain tumors: a bibliometric and clinical trials analysis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/4e4a8c5b19bf4841b7947a7a716eb304
work_keys_str_mv	AT juliansrechberger statusquoandtrendsofintraarterialtherapyforbraintumorsabibliometricandclinicaltrialsanalysis AT fredericthiele statusquoandtrendsofintraarterialtherapyforbraintumorsabibliometricandclinicaltrialsanalysis AT davidjdaniels statusquoandtrendsofintraarterialtherapyforbraintumorsabibliometricandclinicaltrialsanalysis
_version_	1718410770347196416

Status Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis

Ejemplares similares